Various small‐molecule compounds can suppress the oncogenic functions of mutant TP53 or restore the tumor suppressor activities of wild‐type TP53, and although they are not the current standard of care for NSCLC patients they are being tested in some clinical trials.5, 6 However, as for EGFR, effective treatments may require knowledge of the type of patients, with mutant or wild‐type TP53, who can benefit from the targeted therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.